133 related articles for article (PubMed ID: 23052739)
1. Clinical outcome of up-front surgery in patients with asymptomatic, incurable synchronous peritoneal carcinomatosis.
Matsuda K; Hotta T; Takifuji K; Yokoyama S; Oku Y; Hashimoto T; Iwamoto H; Yamaue H
Surg Today; 2013 Sep; 43(9):984-9. PubMed ID: 23052739
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin.
Pelz JO; Chua TC; Esquivel J; Stojadinovic A; Doerfer J; Morris DL; Maeder U; Germer CT; Kerscher AG
BMC Cancer; 2010 Dec; 10():689. PubMed ID: 21176206
[TBL] [Abstract][Full Text] [Related]
3. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D
Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129
[TBL] [Abstract][Full Text] [Related]
4. Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy.
Zani S; Papalezova K; Stinnett S; Tyler D; Hsu D; Blazer DG
J Surg Oncol; 2013 Mar; 107(4):307-11. PubMed ID: 22811275
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer: Results from a Chinese center.
Wu HT; Peng KW; Ji ZH; Sun JH; Zhang Q; Yang XJ; Huang CQ; Li Y
Eur J Surg Oncol; 2016 Jul; 42(7):1024-34. PubMed ID: 27179924
[TBL] [Abstract][Full Text] [Related]
6. The European contribution to "Sugarbaker's protocol" for the treatment of colorectal peritoneal carcinomatosis.
Gómez Portilla A; Cendoya I; Olabarría I; Martínez de Lecea C; Gómez Martínez de Lecea C; Gil A; Martín E; Muriel J; Magrach L; Romero E; Lirola A; Guede N; Moraza N; Fernández E; Kvadatze M; Valdovinos M; Larrabide I; Ruiz de Alegría N; Fernández JL; Castillo C; Rua O; Ulibarrena MA
Rev Esp Enferm Dig; 2009 Feb; 101(2):97-102, 103-6. PubMed ID: 19335045
[TBL] [Abstract][Full Text] [Related]
7. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients.
Elias D; Goere D; Blot F; Billard V; Pocard M; Kohneh-Shahri N; Raynard B
Ann Surg Oncol; 2007 Jun; 14(6):1818-24. PubMed ID: 17356950
[TBL] [Abstract][Full Text] [Related]
8. Unresectable peritoneal carcinomatosis from colorectal cancer: a single center experience.
Hompes D; Boot H; van Tinteren H; Verwaal V
J Surg Oncol; 2011 Sep; 104(3):269-73. PubMed ID: 21465492
[TBL] [Abstract][Full Text] [Related]
9. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.
Elias D; Lefevre JH; Chevalier J; Brouquet A; Marchal F; Classe JM; Ferron G; Guilloit JM; Meeus P; Goéré D; Bonastre J
J Clin Oncol; 2009 Feb; 27(5):681-5. PubMed ID: 19103728
[TBL] [Abstract][Full Text] [Related]
10. Modern chemotherapy mitigates adverse prognostic effect of regional nodal metastases in stage IV colorectal cancer.
Thomay AA; Nagorney DM; Cohen SJ; Sigurdson ER; Truty MJ; Burtness B; Hall MJ; Chun YS
J Gastrointest Surg; 2014 Jan; 18(1):69-74. PubMed ID: 24002765
[TBL] [Abstract][Full Text] [Related]
11. The modified Glasgow prognostic score for early mortality in patients with synchronous peritoneal carcinomatosis from colorectal cancer.
Adachi T; Hinoi T; Hattori M; Egi H; Shimomura M; Saito Y; Sawada H; Miguchi M; Niitsu H; Mukai S; Yano T; Ohdan H
Surg Today; 2015 Nov; 45(11):1396-403. PubMed ID: 25430811
[TBL] [Abstract][Full Text] [Related]
12. HIPEC with oxaliplatin in the treatment of peritoneal carcinomatosis of colorectal origin.
Elias D; Pocard M; Goere D
Cancer Treat Res; 2007; 134():303-18. PubMed ID: 17633062
[No Abstract] [Full Text] [Related]
13. Outcome of surgery for colorectal cancer in the presence of peritoneal carcinomatosis.
Klaver YL; Lemmens VE; de Hingh IH
Eur J Surg Oncol; 2013 Jul; 39(7):734-41. PubMed ID: 23523316
[TBL] [Abstract][Full Text] [Related]
14. Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection.
Nitzkorski JR; Farma JM; Watson JC; Siripurapu V; Zhu F; Matteotti RS; Sigurdson ER
Ann Surg Oncol; 2012 Feb; 19(2):379-83. PubMed ID: 21861213
[TBL] [Abstract][Full Text] [Related]
15. Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy.
Díaz R; Aparicio J; Gironés R; Molina J; Palomar L; Segura A; Montalar J
Clin Colorectal Cancer; 2005 Sep; 5(3):197-202. PubMed ID: 16197623
[TBL] [Abstract][Full Text] [Related]
16. Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Folprecht G; Köhne CH; Lutz MP
Cancer Treat Res; 2007; 134():425-40. PubMed ID: 17633071
[No Abstract] [Full Text] [Related]
17. Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.
Liu JH; Hsieh YY; Chen WS; Hsu YN; Chau GY; Teng HW; King KL; Lin TC; Tzeng CH; Lin JK
Int J Colorectal Dis; 2010 Oct; 25(10):1243-9. PubMed ID: 20574727
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin and molecular-targeted drug therapies improved the overall survival in colorectal cancer patients with synchronous peritoneal carcinomatosis undergoing incomplete cytoreductive surgery.
Adachi T; Hinoi T; Egi H; Shimomura M; Ohdan H
Surg Today; 2015 Aug; 45(8):986-92. PubMed ID: 25156007
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the necessity of primary tumor resection for synchronous metastatic colorectal cancer.
Miyamoto Y; Watanabe M; Sakamoto Y; Shigaki H; Murata A; Sugihara H; Etoh K; Ishimoto T; Iwatsuki M; Baba Y; Iwagami S; Yoshida N; Baba H
Surg Today; 2014 Dec; 44(12):2287-92. PubMed ID: 24623012
[TBL] [Abstract][Full Text] [Related]
20. Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy.
Catalano V; Loupakis F; Graziano F; Torresi U; Bisonni R; Mari D; Fornaro L; Baldelli AM; Giordani P; Rossi D; Alessandroni P; Giustini L; Silva RR; Falcone A; D'Emidio S; Fedeli SL
Br J Cancer; 2009 Mar; 100(6):881-7. PubMed ID: 19259089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
